The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - G1 Therapeutics
Stock and Other Ownership Interests - G1 Therapeutics
Neoadjuvant single-dose trilaciclib prior to combination chemotherapy in patients with early triple-negative breast cancer: Safety, efficacy, and immune correlate data from a phase 2 study.
 
Jeremy Meyer Force
Consulting or Advisory Role - Exact Sciences; G1 Therapeutics; Prime Education
Speakers' Bureau - Gilead Sciences
Research Funding - Xilis
 
Joyce O'Shaughnessy
Honoraria - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Gilead Sciences; GRAIL; Halozyme; HERON; Immunomedics; Ipsen; Lilly; Merck; Myriad Pharmaceuticals; Nektar; Novartis; Ontada/McKesson; Pfizer; Pharmacyclics; Pierre Fabre; Prime Oncology; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax; Synthon; Taiho Oncology; Takeda
Consulting or Advisory Role - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Gilead Sciences; GRAIL; Halozyme; HERON; Immunomedics; Ipsen; Lilly; Merck; Myriad Pharmaceuticals; Nektar; Novartis; Ontada/McKesson; Pfizer; Pharmacyclics; Pierre Fabre; Prime Oncology; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax; Synthon; Taiho Oncology; Takeda
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Seagen
Research Funding - Seagen (Inst)
Travel, Accommodations, Expenses - Abbvie; Agendia; Amgen; AstraZeneca; Celgene; Eisai; GRAIL; Ipsen; Lilly; Myriad Pharmaceuticals; Novartis; Pfizer; Puma Biotechnology; Roche; Sanofi; Seagen
 
Lisa S. Wang
No Relationships to Disclose
 
Kailash Mosalpuria
No Relationships to Disclose
 
Sara A. Hurvitz
Stock and Other Ownership Interests - Ideal Implant (I); ROM Tech (I)
Honoraria - Daiichi Sankyo/Astra Zeneca
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); AstraZeneca/Daiichi Sankyo (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Dignitana (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Greenwich LifeSciences (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Orinove (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Samumed (Inst); sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Pfizer; Roche
 
Shom Goel
Consulting or Advisory Role - G1 Therapeutics; Lilly; Novartis; Pfizer
Research Funding - G1 Therapeutics; Lilly
 
Sarah Ahn
Employment - G1 Therapeutics
 
Subing Cao
Employment - G1 Therapeutics
 
Melissa Russo
Employment - G1 Therapeutics
 
John S. Yi
Employment - G1 Therapeutics
Stock and Other Ownership Interests - G1 Therapeutics
Travel, Accommodations, Expenses - G1 Therapeutics; G1 Therapeutics
 
Taofik Oyekunle
Employment - G1 Therapeutics
 
Amanda Jacobson
No Relationships to Disclose
 
Andrew Paul Beelen
Employment - G1 Therapeutics
Stock and Other Ownership Interests - Amarin Corporation; G1 Therapeutics; Precision Therapeutics
 
Michael A. Danso
Honoraria - Amgen
Consulting or Advisory Role - Immunomedics; Novartis; Pfizer; Seagen